BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

read more >>

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

read more >>

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

read more >>

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

read more >>

Latest news of BEAM Alliance

03 December 2019 - BEAM Alliance

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

The aim of the IMI Antimicrobial Resistance (AMR) Accelerator is to progress the development of new medicines to treat or…

read more >>

18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

read more >>

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

read more >>

19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

read more >>

06 June 2019 - BEAM Alliance

Emergency on planet AMR: a vital pipeline to protect

The sooner we come up with practical solutions, the more SMEs (and currently developed products) we can save from vanishing.…

read more >>

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

read more >>

page 1/3

next

Twitter

View twitter feed

Latest news of BEAM Members

25 February 2020 - ALLECRA THERAPEUTICS

Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections

“The superiority demonstrated in the primary endpoint, at test of cure, combined with a comparable safety profile to that of…

read more >>

11 February 2020 - Da Volterra

Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients

“Results of this study showed that DAV132 could be safely administered to protect patients’ intestinal microbiota from antibiotic-induced disruption, thus…

read more >>

05 February 2020 - MaaT Pharma

MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics

The proceeds will be used to complete the ongoing HERACLES Phase II clinical trial (NCT03359980),of MaaT’s lead compound, MaaT013, in…

read more >>

27 January 2020 - DEINOVE

DEINOVE: Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections

"The start of this Phase II clinical trial is a significant step forward for DEINOVE and a great hope for…

read more >>

07 January 2020 - Centauri Therapeutics Ltd

CARB-X backs Centauri to advance a new platform that combines antibiotic power with the ability to boost the immune system to fight infections caused by drug-resistant bacteria

The award will help Centauri continue the development of ABX01. The novel immunotherapy is in the lead optimization phase of…

read more >>

06 January 2020 - Mutabilis SAS

Novo Holdings REPAIR Impact Fund Invests USD 12 million in Mutabilis and IBT Vaccines

Aleks Engel, Director of the REPAIR Impact Fund, commented: “We are thrilled to have Mutabilis and IBT Vaccines join the…

read more >>

page 1/17

next

Events

13 July 2020

Curious2020 – Future Insight

In 2020 the Future Insight Prize will be given out in the area of Multi Drug Resistance to enable a…

read more >>

26 March 2020

AMR Insights Seminar: Driving Behavioural Change to combat AMR

The Seminar Driving Behavioural Change to combat AMR allows experts from within and outside Europe to give their opinion on…

read more >>

23 March 2020

BIO-Europe, 14th International Partnering Conference

BIO-Europe Spring attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from…

read more >>

22 March 2020

Europe CEO – ​The Perfect Prelude to Partnering

Europe CEO is an invitation-only, off-the-record forum that brings together the global leaders in the biopharma community to network and…

read more >>

12 March 2020

4th AMR Conference Novel Antimicrobial & AMR Diagnostics

This conference is a platform to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments…

read more >>

27 February 2020

REVIVE Webinar: PK/PD murine infection models: Focus on study elements, variability, and interpretation of results

Topics discussed will include: - Understanding and embracing the inherent variability in many components of the murine model. - Demonstrating…

read more >>

27 February 2020

GARDP webinar: PK/PD murine infection models: Focus on study elements, variability, and interpretation of results

Topics discussed will include: - Understanding and embracing the inherent variability in many components of the murine model - Demonstrating…

read more >>

04 February 2020

GARDP webinar: Non-traditional antibacterial therapeutic options and challenges

In this webinar, the following aspects will be presented: - Discovery and early development of “non-traditional” antibacterial approaches is a…

read more >>

21 January 2020

REVIVE Webinar: Testing for the potential of emergence of resistance

This presentation was also part of the 'Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process', jointly…

read more >>

page 1/5

next